Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter: Assessing Pruritus Efficacy With Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidence.

Alimentary pharmacology & therapeutics·2026
Same author

Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026
Same author

Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.

Alimentary pharmacology & therapeutics·2026
Same author

Primary Biliary Cholangitis and Prognostic Models-Reply.

JAMA·2026
Same author

The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Antipruritic effects of the ileal bile acid transporter inhibitor linerixibat.

The lancet. Gastroenterology & hepatology·2026
Same journal

A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs.

Current opinion in immunology·2026
Same journal

Germinal center responses at barrier organ sites.

Current opinion in immunology·2026
Same journal

Ocular sarcoidosis: from clinical signs to targeted interventions.

Current opinion in immunology·2026
Same journal

On or within: spatial determinants of antigen handling in the nasal turbinates.

Current opinion in immunology·2026
Same journal

Decoding the complexity of intestinal immunity with spatial transcriptomics.

Current opinion in immunology·2026
Same journal

Reconsidering the immunological aspects of solid-phase assays for antiphospholipid antibodies detection.

Current opinion in immunology·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

Can we cure primary biliary cholangitis?

Palak J Trivedi1, Gideon M Hirschfield2, M Eric Gershwin3

  • 1National Institute of Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC), University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, Centre for Liver and Gastrointestinal Research, University of Birmingham, Birmingham, UK; Liver Unit, University Hospitals Birmingham National Health Service Foundation Trust, Queen Elizabeth Hospital, Birmingham, UK.

Current Opinion in Immunology
|May 14, 2026
PubMed
Summary
This summary is machine-generated.

Primary biliary cholangitis (PBC) treatments may evolve beyond current bile acid therapies. Future strategies could focus on immune system modulation for a potential cure.

Related Experiment Videos

Last Updated: May 16, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

Area of Science:

  • Hepatology
  • Immunology
  • Gastroenterology

Background:

  • Primary biliary cholangitis (PBC) is a chronic, immune-mediated liver disease.
  • Current treatments focus on slowing disease progression rather than a cure.
  • Therapeutic advances have primarily involved bile acid therapies.

Purpose of the Study:

  • To explore novel therapeutic paradigms for PBC beyond conventional treatments.
  • To investigate autoimmune pathogenesis-rooted strategies for PBC.
  • To re-evaluate the potential for curing PBC.

Main Methods:

  • Review of current literature on PBC pathogenesis and treatment.
  • Exploration of immunomodulatory approaches such as regulatory T-cell modulation.
  • Discussion of nanoparticle-based antigen-specific tolerance.
  • Analysis of epigenetic factors like miRNA dysregulation.
  • Contextualization of broader autoimmune disease concepts with PBC data.

Main Results:

  • Current PBC treatments primarily manage symptoms and slow progression.
  • Emerging strategies target the underlying autoimmune mechanisms of PBC.
  • Regulatory T-cell modulation offers potential for immune tolerance.
  • Nanoparticle-based therapies show promise for antigen-specific tolerance.
  • Epigenetic modifications, including miRNA dysregulation, are implicated in PBC.

Conclusions:

  • PBC treatment may shift towards immune-based therapies.
  • Novel approaches could lead to disease reversal and potential cure.
  • Targeting autoimmune pathways offers a new frontier in PBC management.